PULSE ECONOMICS

Health Technology Assessment (HTA) consulting for drugs, medical devices & diagnostic tools
slider2
Experts in preparing pricing & reimbursement submissions
slider3
Early-stage medtech venture commercialisation & growth strategy advisory
previous arrow
next arrow

Ongoing healthcare system-wide transformation presents immense pressure and new opportunities for medical professionals, pharmaceutical leaders, medical device innovators, and insurers – all of whom are committed to improving patient outcomes while navigating the demands of a value-driven, consumer-focussed, and cost-sensitive operating environment. At Pulse Economics, we can help connect the dots and bring extensive industry experience to every client engagement.

Knowledge is power. We design and support clinical and real-world evidence generation activities focussed on medtech market authorisation and penetration.

We guide clients through the complexities of securing market access and reimbursement, ensuring that products reach patients with optimal pricing.

We help clients, including early-stage ventures, develop a strong commercialisation strategy, supporting growth and effective life cycle management.

Leveraging data to support strategic healthcare decision-making, our analytical services encompass meta-analyses, survival studies, as well as statistical, financial and economic modelling.

We collaborated with Oona for our market access strategy and were thoroughly impressed by her strategic insights, in-depth knowledge of regulatory pathways, reimbursement , and commercialisation. She was instrumental in our approach.

– Founder & CEO, medical device startup (October 2024)

Weve thoroughly enjoyed working with you. It’s been a smooth run with a number of issues addressed then approved by global in record time. I’m also impressed with the teamwork between your consultants and our local team.

– CEO, global pharma company (February 2023)

I have worked on several successful reimbursement projects with Pulse Economics. Their quality of work is impeccable. I wouldn’t hesitate to recommend the team for HTA submissions or clinical literature reviews.

– Market Access Manager, global pharma company (August 2022)